Table 2 Clinicopathologic features of 117 TNBCs of no special type

From: P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas

 

Patients: 117

Median age (years) (range)

59 (26–97)

Tumor size (mm)

 ≤20

60

 >20

57

Tumor grading

 G1

0

 G2

12

 G3

105

Vascular invasions

 Yes

29

 No

83

 Unknown

5

No. of positive nodes

 0

67

 1–3

23

 ≥4

18

 Unknown

9

Ki-67 (%)

 ≤40

70

 >40

47

Chemotherapy

 Yes

83

 No

27

 Unknown

7

Chemotherapeutic regimens

 CMF

15

 CMF+A

11

 CMF+A+T

11

 FEC

17

 FEC+T

16

 A+C

9

 Other

4

  1. Abbreviations: A, anthracycline; C, cyclophosphamide; CMF, cyclophosphamide; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; T, taxane; TNBCs, triple-negative breast carcinomas, methotrexate, 5-fluorouracil.
Back to article page